Search

AnaptysBio's CEO discusses recent 12 week RA data from the company's PD-1 depleter and agonist, rosnilimab, and previews other upcoming catalysts
Daniel Faga goes over the recently released rosnilimab RA data and previews a longer-term follow-up that will be out in the second...
Mar 18